|
|
 Previous Article | Table of Contents | Next Article 
Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal
antibody
S Knox, RT Hoppe, D Maloney, I Gibbs, S Fowler, C Marquez, PJ Cornbleet and R Levy
Department of Radiation Oncology, Stanford University School of Medicine,
CA, USA.
Chimeric anti-CD4 monoclonal antibody was administered intravenously as a
single dose to eight patients with mycosis fungoides. The dose was
escalated throughout the study between patients groups, and individual
patients received 50, 100, or 200 mg per dose. Seven of eight patients
responded to treatment with an average freedom from progression of 25 weeks
(range, 6 to 52 weeks). The treatment was well tolerated, and there was no
clinical evidence of immunosuppression. Following treatment, there was
significant suppression of peripheral blood CD4 counts in all patients for
1 to 22+ weeks. Only one patient made a very low titer human antichimeric
antibody response. All but two patients made primary antibody and T-cell
proliferative responses to a foreign antigen administered 24 hours after
antibody infusion. However, there was generally marked, but temporary
suppression of T-cell proliferative responses in vitro to
phytohemagglutinin (PHA), tetanus toxoid, and normal donor lymphocytes. We
conclude that at the dose levels studied, this antibody (1) had clinical
efficacy against mycosis fungoides; (2) was well tolerated; (3) had a low
level of immunogenicity; (4) decreased T-cell proliferative responses in
vitro, and (5) did not induce tolerance to a foreign antigen.
Volume 87,
Issue 3,
pp. 893-899,
02/01/1996
Copyright © 1996 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. A. Rider, C. E.G. Havenith, R. de Ridder, J. Schuurman, C. Favre, J. C. Cooper, S. Walker, O. Baadsgaard, S. Marschner, J. G.J. vandeWinkel, et al.
A Human CD4 Monoclonal Antibody for the Treatment of T-Cell Lymphoma Combines Inhibition of T-Cell Signaling by a Dual Mechanism with Potent Fc-Dependent Effector Activity
Cancer Res.,
October 15, 2007;
67(20):
9945 - 9953.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. H. Kim, M. Duvic, E. Obitz, R. Gniadecki, L. Iversen, A. Osterborg, S. Whittaker, T. M. Illidge, T. Schwarz, R. Kaufmann, et al.
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma
Blood,
June 1, 2007;
109(11):
4655 - 4662.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Lundin, H. Hagberg, R. Repp, E. Cavallin-Stahl, S. Freden, G. Juliusson, E. Rosenblad, G. Tjonnfjord, T. Wiklund, and A. Osterborg
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome
Blood,
June 1, 2003;
101(11):
4267 - 4272.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Siegel, T. Pandolfino, J. Guitart, S. Rosen, and T. M. Kuzel
Primary Cutaneous T-Cell Lymphoma: Review and Current Concepts
J. Clin. Oncol.,
August 15, 2000;
18(15):
2908 - 2925.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
